Table of Contents

Chapter 1. Transplantation Market: Methodology and Scope

1.1. Market Segmentation & Scope
1.1.1. Product type
1.1.2. Application type
1.1.3. End use
1.1.4. Region scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2

Chapter 2. Transplantation Market: Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product type outlook
2.2.2. Application type outlook
2.2.3. End use outlook
2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Transplantation Market: Variables, Trends & Scope

3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Increasing incidence of organ failure
3.4.1.2. Technological advancement in transplantation method
3.4.1.3. Developed tissue banks
3.4.2. Market restraint analysis
3.4.2.1. Shortage of organ donors
3.4.2.2. Ethical and cultural issues
3.4.3. Key opportunities prioritized
3.4.3.1. Key opportunities prioritized, by Product
3.4.3.2. Key opportunities prioritized, by application
3.4.3.3. Key opportunities prioritized, by end use
3.5. Transplantation Market Analysis Tools
3.5.1. Industry analysis - Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. Major deals & strategic alliances analysis
3.5.4. Market entry strategies

Chapter 4. Transplantation Market by Product Type

4.1. Definitions and Scope
4.1.1. Tissue products
4.1.1.1. Market estimates and forecast, 2023-2032 (USD Million)
4.1.2. Immunosuppressive drugs
4.1.2.1. Market estimates and forecast, 2023-2032 (USD Million)
4.1.3. Preservation Solutions
4.1.3.1. Market estimates and forecast, 2023-2032 (USD Million)

Chapter 5. Transplantation Market: Application Type

5.1. Definitions and Scope
5.1.1. Tissue Transplantation
5.1.2. Organ Transplantation
5.2. Product Market Share, 2022 & 2030
5.3. Segment Dashboard
5.4. Global Transplantation Market by Application Type Outlook
5.4.1. Tissue Transplantation
5.4.1.1. Market estimates and forecast, 2023-2032 (USD Million)
5.4.2. Organ Transplantation
5.4.2.1. Market estimates and forecast, 2023-2032 (USD Million)

Chapter 6. Transplantation Market: End-Use

6.1. Definitions and Scope
6.1.1. Hospitals
6.1.2. Transplantation centers
6.1.3. Others
6.2. Product Market Share, 2022 & 2030
6.3. Segment Dashboard
6.4. Global Transplantation Market End Use Channel Outlook
6.4.1. Hospitals
6.4.1.1. Market estimates and forecast, 2023-2032 (USD Million)
6.4.2. Transplantation centers
6.4.2.1. Market estimates and forecast, 2023-2032 (USD Million)
6.4.3. Others
6.4.3.1. Market estimates and forecast, 2023-2032 (USD Million)

Chapter 7. Transplantation Market: Country

7.1. Regional market share analysis, 2022 & 2030
7.2. Regional Marketplace: Key Takeaways
7.3. North America
7.3.1. SWOT Analysis
7.3.2. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.3.3. U.S.
7.3.3.1. Country Dynamics
7.3.3.2. Country Variables
7.3.3.3. Competitive Landscape
7.3.3.4. Regulatory/Reimbursement Framework
7.3.3.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.3.4. Canada
7.3.4.1. Country Dynamics
7.3.4.2. Country Variables
7.3.4.3. Competitive Landscape
7.3.4.4. Regulatory/Reimbursement Framework
7.3.4.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.4. Europe
7.4.1. SWOT Analysis
7.4.2. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.4.3. UK
7.4.3.1. Country Dynamics
7.4.3.2. Country Variables
7.4.3.3. Competitive Landscape
7.4.3.4. Regulatory/Reimbursement Framework
7.4.3.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.4.4. Germany
7.4.4.1. Country Dynamics
7.4.4.2. Country Variables
7.4.4.3. Competitive Landscape
7.4.4.4. Regulatory/Reimbursement Framework
7.4.4.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.4.5. France
7.4.5.1. Country Dynamics
7.4.5.2. Country Variables
7.4.5.3. Competitive Landscape
7.4.5.4. Regulatory/Reimbursement Framework
7.4.5.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.4.6. Italy
7.4.6.1. Country Dynamics
7.4.6.2. Country Variables
7.4.6.3. Competitive Landscape
7.4.6.4. Regulatory/Reimbursement Framework
7.4.6.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.4.7. Spain
7.4.7.1. Country Dynamics
7.4.7.2. Country Variables
7.4.7.3. Competitive Landscape
7.4.7.4. Regulatory/Reimbursement Framework
7.4.7.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.4.8. Denmark
7.4.8.1. Country Dynamics
7.4.8.2. Country Variables
7.4.8.3. Competitive Landscape
7.4.8.4. Regulatory/Reimbursement Framework
7.4.8.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.4.9. Sweden
7.4.9.1. Country Dynamics
7.4.9.2. Country Variables
7.4.9.3. Competitive Landscape
7.4.9.4. Regulatory/Reimbursement Framework
7.4.9.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.4.10. Norway
7.4.10.1. Country Dynamics
7.4.10.2. Country Variables
7.4.10.3. Competitive Landscape
7.4.10.4. Regulatory/Reimbursement Framework
7.4.10.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.5. Asia Pacific
7.5.1. SWOT Analysis
7.5.2. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.5.3. Japan
7.5.3.1. Country Dynamics
7.5.3.2. Country Variables
7.5.3.3. Competitive Landscape
7.5.3.4. Regulatory/Reimbursement Framework
7.5.3.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.5.4. China
7.5.4.1. Country Dynamics
7.5.4.2. Country Variables
7.5.4.3. Competitive Landscape
7.5.4.4. Regulatory/Reimbursement Framework
7.5.4.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.5.5. India
7.5.5.1. Country Dynamics
7.5.5.2. Country Variables
7.5.5.3. Competitive Landscape
7.5.5.4. Regulatory/Reimbursement Framework
7.5.5.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.5.6. Australia
7.5.6.1. Country Dynamics
7.5.6.2. Country Variables
7.5.6.3. Competitive Landscape
7.5.6.4. Regulatory/Reimbursement Framework
7.5.6.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.5.7. Thailand
7.5.7.1. Country Dynamics
7.5.7.2. Country Variables
7.5.7.3. Competitive Landscape
7.5.7.4. Regulatory/Reimbursement Framework
7.5.7.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.5.8. South Korea
7.5.8.1. Country Dynamics
7.5.8.2. Country Variables
7.5.8.3. Competitive Landscape
7.5.8.4. Regulatory/Reimbursement Framework
7.5.8.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.6. Latin America
7.6.1. SWOT Analysis
7.6.2. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.6.3. Brazil
7.6.3.1. Country Dynamics
7.6.3.2. Country Variables
7.6.3.3. Competitive Landscape
7.6.3.4. Regulatory/Reimbursement Framework
7.6.3.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.6.4. Mexico
7.6.4.1. Country Dynamics
7.6.4.2. Country Variables
7.6.4.3. Competitive Landscape
7.6.4.4. Regulatory/Reimbursement Framework
7.6.4.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.6.5. Argentina
7.6.5.1. Country Dynamics
7.6.5.2. Country Variables
7.6.5.3. Competitive Landscape
7.6.5.4. Regulatory/Reimbursement Framework
7.6.5.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.7. MEA
7.7.1. SWOT Analysis
7.7.2. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.7.3. South Africa
7.7.3.1. Country Dynamics
7.7.3.2. Country Variables
7.7.3.3. Competitive Landscape
7.7.3.4. Regulatory/Reimbursement Framework
7.7.3.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.7.4. Saudi Arabia
7.7.4.1. Country Dynamics
7.7.4.2. Country Variables
7.7.4.3. Competitive Landscape
7.7.4.4. Regulatory/Reimbursement Framework
7.7.4.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.7.5. UAE
7.7.5.1. Country Dynamics
7.7.5.2. Country Variables
7.7.5.3. Competitive Landscape
7.7.5.4. Regulatory/Reimbursement Framework
7.7.5.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)
7.7.6. Kuwait
7.7.6.1. Country Dynamics
7.7.6.2. Country Variables
7.7.6.3. Competitive Landscape
7.7.6.4. Regulatory/Reimbursement Framework
7.7.6.5. Market estimates and forecast, 2023-2032 (Revenue, USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.2.1. Innovators
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2022
8.3.4. Abbvie Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Procedure benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Arthrex Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Procedure benchmarking
8.3.5.4. Strategic initiatives
8.3.6. BioLife Solutions Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Procedure benchmarking
8.3.6.4. Strategic initiatives
8.3.7. TransMedics Inc.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Procedure benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Medtronic plc
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Procedure benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Novartis AG
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Procedure benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Teva Pharmaceuticals Industries Ltd.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Procedure benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Veloxis Pharmaceuticals A/S
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Procedure benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Stryker Corporation
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Procedure benchmarking
8.3.12.4. Strategic initiatives
8.3.12. Zimmer Biomet Holdings Inc.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Procedure benchmarking
8.3.12.4. Strategic initiatives
8.3.12. Other
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Procedure benchmarking
8.3.12.4. Strategic initiatives